BioWorld

April 25, 2005

Lifted By Higher Product Sales, Amgen Beats Consensus EPS

Beating Wall Street estimates, Amgen Inc. performed well in the first quarter, reporting strong revenue for most of its products, despite Medicare reimbursement changes. (BioWorld Today) Read More

Solexa Signs Deal To Raise $32.5M, Advance Platform

Novel Approach To Synthesis Causing Tetracycline Variety

Recent Stem Cell Bill Forbids Human Reproductive Cloning

Hamilton Pharmaceuticals' First Financing: $11M For CNS Drugs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 25, 2026.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026